( C L A R I T H R O...

CLARITHROMYCIN has been used in other treatment regimens for the
eradication of H. Pylori, including:
(CLARITHROMYCIN)
COMPOSITION
NEO-KLAR 250 mg Tablets:
Each Film Coated Tablet Contains:
Clarithromycin U.S.P................... 250 mg.
NEO-KLAR 500 mg Tablets:
Each Film Coated Tablet Contains:
Clarithromycin U.S.P................... 500 mg.
NEO-KLAR Granules:
When mixed as directed each teaspoonful (5 ml) contains:
Clarithromycin ................... 125 mg.
PHARMACOKINETICS
INFECTIONS
IN
PATIENTS
WITH
MYCOBACTERIAL
Steady-state concentrations of CLARITHROMYCIN and 14-OH
CLARITHROMYCIN observed following administration of usual doses to
adult patients with HIV infection were similar to those observed in normal
subjects. However, at the higher doses, which may be required to treat
mycobacterial infections, CLARITHROMYCIN concentrations were much
higher than those observed at the usual doses. In adult HIV-infected patients
taking 1000-2000 mg/day in two divided doses, steady state
CLARITHROMYCIN Cmax values ranged from 2-4 mcg/ml and 5-10 mcg/ml,
respectively. Cmax values as high as 27 mcg/ml have been observed in HIVinfected adult patients taking 4000 mg/day in two divided doses. Elimination
half-lives appeared to be lengthened at these higher doses as compared to
that seen with usual doses in normal subjects. The higher plasma
concentrations and longer elimination half-lives observed at these doses are
consistent with the known nonlinearity in CLARITHROMYCIN
pharmacokinetics. In children with HIV infection taking 15-30 mg/kg/day of
CLARITHROMYCIN in two divided doses steady-state Cmax values
generally ranged from 8 to 20 mcg/ml. However, Cmax values as high as 23
mcg/ml have been observed in HIV infected paediatric patients taking 30
mg/kg/day in two divided doses as CLARITHROMYCIN PAEDIATRIC
SUSPENSION. Elimination half-lives appeared to be lengthened at these
higher doses as compared to that observed with usual doses in normal
subjects. The higher plasma concentrations and longer elimination half-lives
observed at these doses are consistent with the known nonlinearity in
CLARITHROMYCIN pharmacokinetics.
MUTAGENICITY
Studies to evaluate the mutagenic potential of CLARITHROMYCIN were
performed using both nonactivated and rat-liver-microsome-activated test
systems (Ames test). Results of these studies provided no evidence of
mutagenic potential at drug concentrations of 25 mcg/petriplate or less. At a
concentration of 50 mcg the drug was toxic for all strains tested.
INDICATIONS:
CLARITHROMYCIN is indicated for treatment of infections due to
susceptible organisms, such infections include:
1- Lower respiratory tract infections (e.g., Bronchitis, pneumonia)
2- Upper respiratory tract infections (e.g., Pharyngitis, sinusitis)
3- Acute otitis media in children.
4- Skin and soft tissue infections.
5- Disseminated or localized mycobacterial infections due to
Mycobacterium avium, Mycobacterium intracellulare, Localized
infections due to Mycobacterium chelonae, Mycobacterium fortuitum.
or Mycobacterium kansasaii.
6- CLARITHROMYCIN in the presence of acid suppression is indicated for
the eradication of H. pylori, resulting in decreased recurrence of
duodenal ulcer.
The safety of
Usage
during
pregnancy
and lactation:
CLARITHROMYCIN for use during pregnancy and breast-feeding of infants
has not been established. CLARITHROMYCIN is excreted into human
breast milk.
Fertility, Reproduction and Teratogenicity:
Fertility and reproduction
studies have shown, daily dosages of 150-160 mg/kg/day to male and female
rats caused no adverse effects on the estrous cycle, fertility, parturition, and
number and viability of offspring. Two Teratogenicity studies in both Wistar
(p.o.) and sprague Dawley (p.o. and I.V.) Rats 1 study in New Zealand white
rabbits and 1 study in cynomologous monkeys failed to demonstrate any
Teratogenicity from CLARITHROMYCIN. Only in 1 additional study in
Sprague-Dawley rats at similar doses and essentially similar conditions did
a very low, statistically insignificant incidence (approximately 6%) of
cardiovascular anomalies occurred. These anomalies appeared to be due to
spontaneous expression of genetic changes within the colony).
OVERDOSAGE
Reports indicate that the ingestion of large amounts of CLARITHROMYCIN
can be expected to produce gastrointestinal symptoms. One patient who
had a history of bipolar disorder ingested 8 grams of CLARITHROMYCIN
and showed altered mental status, paranoid behaviour, hypokalemia and
hypoxemia. Allergic reactions accompanying overdosage should be treated
by the prompt elimination of unabsorbed drug and supportive measures. As
with other macrolides, CLARITHROMYCIN serum levels are not expected
to be appreciably affected by hemodialysis or peritoneal dialysis.
FURTHER INFORMATION
Helicobacter pylori is strongly associated with peptic ulcer disease. Ninety
(90) to 100 % of patients with duodenal ulcers are infected with this
pathogen. Eradication of H. Pylori has been shown to reduce the rate of
duodenal ulcer recurrence, thereby reducing the need for maintenance antisecretory therapy. In 4 well controlled, double-blind studies H. Pylori infected
duodenal ulcer patients received eradication therapy with
CLARITHROMYCIN 500 mg TID and omeprazole 40 mg daily for 14 days
followed by omeprazole 40 mg (study A) or omeprazole 20 mg (studies B,C
and D) daily for and additional 14 days: patients in each control group
received omeprazole alone for 28 days.
In study A, H. Pylori was eradicated in over 80 % of patients who received
CLARITHROMYCIN and omeprazole, and in only 1 % of patients receiving
omeprazole alone. In studies B, C and D, the combined eradication rate
was over 70 % in-patients receiving CLARITHROMYCIN and omeprazole,
and less than 1 % in-patients receiving omeprazole alone. In each study, the
rate of ulcer recurrence at 6 months was statistically lower in the
CLARITHROMYCIN and omeprazole treated patients when compared to
patients receiving omeprazole alone.
CLARITHROMYCIN plus amoxicillin and omeprazole
CLARITHROMYCIN plus tinidazole and omeprazole
CLARITHROMYCIN plus Tetracycline, bismuth subsalicylate, and
ranitidine
CLARITHROMYCIN puls Iansoprazole
CLARITHROMYCIN plus amoxicillin and lansoprazole
DOSAGE AND ADMINISTRATION
NEO-KLAR Tablets:
The usual recommended dosage of CLARITHROMYCIN is one 250 mg
tablet twice daily. In more severe infections the dosage can be increased to
500 mg twice daily. The usual duration of therapy is 6 to 14 days.
In patients with renal impairment with creatinine clearance less than
30 ml/min, the dosage of CLARITHROMYCIN should be reduced by onehalf, i.e., 250 mg once daily, or 250 mg twice daily in more severe infections.
Treatment should not be continued beyond 14 days in these patients.
Dosage in patients with mycobacterial infection: The recommended starting
dose for adults with mycobacterial infections is 500 mg BID. If no clinical or
bacteriologic response is observed in 3 to 4 weeks, the dose may be
increased to 1000 mg BID.
Treatment of disseminated MAC infections in AIDS patients should be
continued as long as clinical and microbiological benefit is demonstrated.
CLARITHROMYCIN should be used in conjunction with other
antimycobacterial agents.
Treatment of other nontuberculous mycobacterial infections should
continue at the discretion of the physician.
Eradication of H. Pylori: The recommended dose of CLARITHROMYCIN is
500 mg TID for 14 days.
NEO-KLAR Granules:
The recommended daily dosage of CLARITHROMYCIN PAEDIATRIC
SUSPENSION (125 mg / 5 ml) in children is 7.5 mg/kg b.i.d. Upto a maximum
dose of 500 mg b.i.d. for non mycobacterial infections. The usual duration of
treatment is for 5 to 10 days depending on the pathogen involved and the
severity of the condition. Treatment for Streptococcal pharyngitis should be
at least 10 days. The prepared suspension can be taken with or without
meals, and can be taken with milk.
The following table is a suggested guide for determining dosage:
CLARITHROMYCIN PAEDIATRIC DOSAGE IN CHILDREN
Based on Body weight in kg/lb
Dosage in standard 5 ml
Teaspoonful given twice daily
125mg/5ml
Weight*
08-11 kg / 18-25 lb
12-19 kg / 26-43 lb
20-29 kg / 44-64 lb
30-40 kg / 65-88 lb
0.5
1.0
1.5
2.0
*Children. 8 kg / 18 lb should be dosed on per kg/per lb. basis (approx. 7.5
mg/kg or 3.4 mg/lb b.i.d.)
Dosage in patients with renal impairment: In children with creatinine
clearance less than 30 ml/min, the dosage of CLARITHROMYCIN should be
reduced by one-half, i.e., upto 250 mg once daily, or 250 mg twice daily in
more severe infections. Dosage should not be continued beyond 14 days in
these patients.
Dosage in patients with mycobacterial infections: In children with
disseminated or localized mycobacterial infections (M. avium, M.
intracellulare, M. Chelonae, M. Fortuitum, M. Kansasii), the recommended
dose is 15-30 mg/kg CLARITHROMYCIN per day in two divided doses.
Treatment with CLARITHROMYCIN should continue as long as clinical
benefit is demonstrated. The addition of other anti-mycobacterial agents
may be of benefit.
DOSAGE GUIDELINES FOR PAEDIATRIC AIDS PATIENTS
Based on Body Weight
Dosage in standard
5 ml Teaspoonful given twice daily
(Clarithromycin 125mg/5ml)
Weight*
Kg
08-11
12-19
20-29
30-40
Lb
18-25
26-43
44-64
65-88
125 mg/kg
0.5
1.0
1.5
2.0
30 mg/kg
1
2
3
4
*Children, 8kg (18 lbs) should be dosed on a per kg basis (15 to 30
mg/kg/day.)
DIRECTIONS FOR PREPARING SUSPENSION:
Add freshly boiled and cool water in bottle and shake well to make 60 ml
up to the red mark on the bottle.
INSTRUCTIONS
- Protect from heat, sunlight & moisture.
- Store below 30 C.
- Keep out of the reach of children.
PRESENTATION
NEO-KLAR Tablet 250 mg
In pack of 10 Tablets
NEO-KLAR Tablet 500 mg
In pack of 10 Tablets
NEO-KLAR Suspension
Pack of 60 ml.